This reports provides a data-driven overview of the current and future competitive landscape in MD therapeutics.
More than 208 million total prevalent cases of MD are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for MD.
The marketed drugs space for MD is dominated by estrogen receptor agonists.
Out of 28 molecules in the pipeline for MD, the late-stage pipeline includes two drugs in pre-registration and four drugs in Phase III.
Commercial sponsors lead the clinical trials space for MD over the past 10 years, with Bayer sponsoring the highest number of trials overall (15 trials) followed by Astellas Pharma (13 trials).
In deals involving companies developing MD assets, partnership was the most prevalent deal type in North America and asset transactions were the most prevalent deal type in Europe.
Scope
GlobalData’s MD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the MD market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MD market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Findings
Disease Overview
Disease Etiology
Epidemiology Overview
Epidemiology Overview - Total Prevalent Cases of MD in 2023 and 2028
Treatment Overview
Treatment Guidelines
Marketed Drugs Assessment
Marketed Drugs - Leading Marketed Drugs in MD
Marketed Drugs - Overview by Mechanism of Action
Marketed Drugs - Overview by Route of Administration
Marketed Drugs - Overview by Molecule Type
Marketed Drug Profile - Astellas's Veozah
Marketed Drug Profile - Pfizer's Duavee/Duavive
Marketed Drug Profile - Bayer's Allurene/Angeliq/Angemin
Marketed Drug Profile - Theramex Healthcare's Bijuva
Marketed Drug Profile - Hisamitsu Pharmaceutical's Minivelle
Marketed Drug Profile - Sebela Pharmaceuticals's Brisdelle
Pricing and Reimbursement Assessment
Marketed Drugs - Pricing and Reimbursement
Pipeline Drugs Assessment
Pipeline Drugs Overview - Late-Stage Pipeline Drugs in MD
Pipeline Drugs - Overview by Development Stage
Pipeline Drugs - Overview by Mechanism of Action
Pipeline Drugs - Overview by Route of Administration
Pipeline Drugs - Overview by Molecule Type
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in MD
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in Women's Health and MD
Clinical Trials Assessment
Clinical Trials in MD - Historical Overview
Clinical Trials in MD - Overview by Phase
Clinical Trials in MD - Overview by Status
Clinical Trials in MD - Overview by Phase for Ongoing and Planned Trials
Clinical Trials in MD - Trials with a Virtual Component
Clinical Trials in MD - Geographic Overview
Clinical Trials in MD - Single-Country and Multinational Trials by Region
Clinical Trials in MD - Top Sponsors with Breakdown by Phase
Clinical Trials in MD - Top Sponsors with Breakdown by Status
Clinical Trials in MD - Overview by Endpoint Status
Clinical Trials in MD - Overview by Race and Ethnicity
Clinical Trials in MD - Enrollment Data
Clinical Trials in MD - Overview of Sites by Geography
Clinical Trials in MD - Top 20 Countries for Trial Sites